1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

 
• By John Davis

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.  

Stepping stones
Alexion is taking steps to add further indications to its next-generation complement inhibitor • Source: Shutterstock

Alexion Pharmaceuticals Inc.'s progress in developing a next-generation successor for its aging blockbuster, Soliris (eculizumab) are being viewed in a positive light by analysts, who have been upbeat about late-stage clinical results released earlier this week involving the longer-acting successor, Ultomiris, in a second potential indication.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By Kevin Grogan

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

 
• By Joseph Haas

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

Regeneron Will Move Two Factor XI Agents Into Phase III

 
• By Joseph Haas

With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.

ASH: Pfizer’s Hemophilia A Gene Therapy May Have Slight Liver Safety Advantage

 
• By Mandy Jackson

Hematologists’ concerns about hepatoxicity with hemophilia A gene therapies may limit use, but Phase III data for Pfizer’s candidate at ASH show a lower rate of ALT increases than seen with BioMarin’s Roctavian.

More from Therapy Areas

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.